Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Evotec Spin-Off Eyes Early Clinical POC With Immune Tolerance Platform

This article was originally published in Scrip

Executive Summary

Evotec AG of Germany has spun out a drug discovery company called Topas Therapeutics GmbH. It is being launched with a €14m series A financing round led by VC firm Epidarex Capital, of which Eli Lilly is an investor. The round also included EMBL Ventures, Gimv and Evotec.